Similarly, to prevent or slow DN, the American Diabetes Association (ADA) recommends early and intensive glycemic control, as well as optimization of weight, blood pressure and lipid profile, along with regular assessment and treatment of neuropathic pain [11]
One drug class that has garnered interest in the management of neuro-ophthalmic conditions is glucagon-like peptide 1 receptor agonists (GLP-1RAs)
It maintains the efficacy of existing injectables and offers the significant benefit of room temperature storage, eliminating the need for a cold storage system
The glucagon-like peptide-1 receptor agonist reduces inflammation and bloodbrain barrier breakdown in an astrocyte-dependent manner in experimental stroke
Its given me hope where I thought hope was lost
Of course, anyone with a masters degree in clinical nutrition or related fields will come away with an even better understanding of coping with side effects